(Press-News.org)
VIDEO:
This three-dimensional reconstruction of part of a human colorectal tumor shows widespread infection with oncolytic vaccinia virus (green).
Click here for more information.
Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other institutions today reported promising results of a world-first cancer therapy trial in renowned journal Nature. The trial is the first to show that an intravenously-delivered viral therapy can consistently infect and spread within tumours without harming normal tissues in humans. It is also the first to show tumour-selective expression of a foreign gene after intravenous delivery.
The trial involved 23 patients (including seven at The Ottawa Hospital), all with advanced cancers that had spread to multiple organs and failed to respond to standard treatments. The patients received a single intravenous infusion of a virus called JX-594, at one of five dose levels, and biopsies were obtained eight to 10 days later. Seven of eight patients (87 per cent) in the two highest dose groups had evidence of viral replication in their tumour, but not in normal tissues. All of these patients also showed tumour-selective expression of a foreign gene that was engineered into the virus to help with detection. The virus was well tolerated at all dose levels, with the most common side effect being mild to moderate flu-like symptoms that lasted less than one day.
"We are very excited because this is the first time in medical history that a viral therapy has been shown to consistently and selectively replicate in cancer tissue after intravenous infusion in humans," said Dr. John Bell, a Senior Scientist at OHRI, Professor of Medicine at uOttawa and senior co-author on the publication. "Intravenous delivery is crucial for cancer
treatment because it allows us to target tumours throughout the body as opposed to just those that we can directly inject. The study is also important because it shows that we can use this approach to selectively express foreign genes in tumours, opening the door to a whole new suite of targeted cancer therapies."
Dr. Bell and his team have been investigating cancer-fighting (oncolytic) viruses at OHRI for more than 10 years. JX-594 was developed in partnership with Jennerex Inc., a biotherpeutics company co-founded by Dr. Bell in Ottawa and Dr. David Kirn in San Francisco. JX-594 is derived from a strain of vaccinia virus that has been used extensively as a live vaccine against smallpox. It has a natural ability to replicate preferentially in cancer cells, but it has also been genetically engineered to enhance its anti-cancer properties.
"Oncolytic viruses are unique because they can attack tumours in multiple ways, they have very mild side effects compared to other treatments, and they can be easily customized for different kinds of cancer," said Dr. Bell. "We're still in the early stages of testing these viruses in patients, but I believe that someday, viruses and other biological therapies could truly transform our approach for treating cancer."
Although the current trial was designed primarily to assess safety and delivery of JX-594, anti-tumour activity was also evaluated. Six of eight patients (75%) in the two highest dose groups experienced a shrinking or stabilization of their tumour, while those in lower dose groups were less likely to experience this effect.
"These results are promising, especially for such an early-stage trial, with only one dose of therapy," said Dr. Bell. "But of course, we will need to do more trials to know if this virus can truly make a difference for patients. We are working hard to get these trials started, and at the same time, we are also working in the laboratory to advance our understanding of these viruses and figure out how best to use them."
"On behalf of everyone involved in this research, I want to thank all the courageous patients who participated in this trial," added Dr. Bell. I also want to thank the community and funding organizations for their generous support."
INFORMATION:
About the Study Funders and Authors
This research was supported by Jennerex Inc., the Terry Fox Foundation, the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, the Canada Foundation for Innovation, the Natural Sciences and Engineering Research Council of Canada and the Republic of Korea. OHRI / uOttawa authors on the paper include Dr. John Bell, Dr. Derek Jonker, Dr. Laura Chow, Dr. Fabrice Le Boeuf, Joe Burns, Laura Evgin, Naomi De Silva, Sara Cvancic, Dr. Kelley Parato, Dr. Jean-Simon Diallo and Dr. Manijeh Daneshmand, as well as alumnus Dr. Caroline Breitbach. Other authors are listed in the full publication, available at www.nature.com.
About OHRI
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University's Faculties of Medicine and Health Sciences. The OHRI includes more than 1,500 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca
Note: Patients interested in participating in clinical trials should discuss this with their oncologist. Dr. Bell is not a medical doctor and is not able to enroll patients in clinical trials.
Results of world-first viral therapy trial in cancer patients published in Nature
2011-09-01
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Stanford scientists discover blood factors that appear to cause aging in brains of mice
2011-09-01
STANFORD, Calif. — Memo to mature, health-minded vampires: You might want to consider limiting your treats to victims under age 30.
In a study to be published Sept. 1 in Nature, Stanford University School of Medicine scientists have found substances in the blood of old mice that makes young brains act older. These substances, whose levels rise with increasing age, appear to inhibit the brain's ability to produce new nerve cells critical to memory and learning.
The findings raise the question of whether it might be possible to shield the brain from aging by eliminating ...
BUSM professor outlines best practices for treating victims of sexual assault
2011-09-01
(BOSTON) – Judith A. Linden, MD, associate professor of emergency medicine at Boston University School of Medicine (BUSM) and vice chair for education in the department of emergency medicine at Boston Medical Center (BMC), has written an review article on the treatment of adult victims of sexual assault in an acute care setting that will run in the Sept. 1 issue of the New England Journal of Medicine. The article, which utilizes a clinical vignette to illustrate evaluation and treatment protocols, was written to educate primary care and emergency physicians about the best ...
Dangerous arrhythmia analyzed in a heartbeat
2011-09-01
Just one second, one heartbeat.
That's what is needed for a new, noninvasive functional imaging technology to record data for locating the source in the heart of a dangerous cardiac arrhythmia called ventricular tachycardia (VT).
VT is an abnormal, fast beating of the heart, which, if ignored, can lead to ventricular fibrillation, which causes some 400,000 cases of sudden death yearly in the United States alone.
The technique, developed by a Washington University in St. Louis scientist, is called Electrocardiographic Imaging (ECGI). It combines computerized tomography ...
First lizard genome sequenced
2011-09-01
The green anole lizard is an agile and active creature, and so are elements of its genome. This genomic agility and other new clues have emerged from the full sequencing of the lizard's genome and may offer insights into how the genomes of humans, mammals, and their reptilian counterparts have evolved since mammals and reptiles parted ways 320 million years ago. The researchers who completed this sequencing project reported their findings August 31 online in the journal Nature.
The green anole lizard (Anolis carolinensis) – a native of the Southeastern United States – ...
Research gives new hope to those with rare vascular cancer
2011-09-01
A specific genetic alteration has been discovered as a defining feature of epithelioid hemangioendothelioma (EHE), a rare but devastating vascular cancer. These findings have also been used to develop a new diagnostic test for this blood vessel disease.
An international research effort led by Brian Rubin, M.D., Ph.D., of Cleveland Clinic's Pathology and Laboratory Medicine Institute and Lerner Research Institute, devised an innovative approach to reveal the genetic alteration thought to cause EHE, which is considered uncommon: it comprises less than one percent of all ...
Adjuvant therapy perhaps not necessary for older breast cancer patients
2011-09-01
Breast cancer patients over the age of 60 with early-stage, hormone-responsive small tumors who forego adjuvant endocrine, also called hormonal therapy, are not at an increased risk of mortality compared to women of the same age without breast cancer, according to a study published Aug. 31 in the Journal of the National Cancer Institute.
The use of hormonal therapy has increased in breast cancer patients overall, and the 2009 St. Gallen International Breast Cancer Conference recommended hormonal therapy for almost all patients with hormone-responsive disease. But previous ...
UBC researchers find a new culprit in Alzheimer’s disease: Too many blood vessels
2011-09-01
University of British Columbia scientists may have uncovered a new explanation for how Alzheimer's disease destroys the brain – a profusion of blood vessels.
While the death of cells, whether they are in the walls of blood vessels or in brain tissue, has been a major focus of Alzheimer's disease research, a team led by Wilfred Jefferies, a professor in UBC's Michael Smith Laboratories, has shown that the neurodegenerative disease might in fact be caused by the propagation of cells in blood vessel walls.
Examining brain tissue from mouse models of Alzheimer's disease, ...
EUR10, 000 Guaranteed on Golden Riviera's Latest Slots Tourney
2011-09-01
Golden Riviera Online Casino recently announced that they will be hosting a Guaranteed EUR10,000 Slots Tournament on the superb Video Slot, Hitman. Golden Rivera was the first in the industry to host a Slots Tournament of this kind and magnitude and to say that the previous EUR10K tourneys were an astounding success with its patrons would be an understatement.
Casino Manager, Emily Alessi, released this statement to the press: "The time has come again for our famous EUR10,000 Guaranteed FreeRoll Slots Tourney. Every one of our previous EUR10K tourneys has had such ...
Leicester scientists deploy space-age technologies at science-fiction style 'sick bay'
2011-09-01
A new hi-tech £1million-plus non-invasive disease detection facility, developed by the University of Leicester, has been unveiled today (Sept 1st 2011) for use in Leicester Royal Infirmary's A&E department.
It is designed to detect the "sight, smell and feel" of disease without the use of invasive probes, blood tests, or other time-consuming and uncomfortable procedures.
Scientists use three different types of cutting-edge technology in combination under a range of situations. All the methods are non-invasive, and could speed up diagnosis.
Scientists have surrounded ...
Robert Lauri: Discovery of Unreleased Timeless Musical Creations
2011-09-01
Robert Lauri reveals a new window of his musical creativity by now offering listeners some previously unreleased timeless melodies... all of them simply stunning.
The artist introduces us to some of the songs performed in English by Lorraine S'. All of his melodies and arrangements offer an opportunity for today's artists and performers.
For example, Robert Lauri first introduces us to the selections My Friend, Promised Land and Sunset. Wix widgets will be shared on Robert Lauri's social networking sites as well as on his music sites.
During his long musical ...